IRCT20160809029275N2招募中2 期
Safety and immuno-modulation evaluation of treatment with intravenous and spinal cord injections of of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS).
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Patients with ALS approved by neurologist with 31-46 ALSFRS-R score
- •Patients should be treated with a fixed dose of Rilozule 3 months ago.
- •Patients should not be detrimental to any other chronic disease and do not use ventilator.
排除标准
- •Patients with malignancy
- •Patients with other chronic disruptive diseases
- •Others Neurodegenerative disease
研究者
相似试验
已完成
2 期
To study the effect of Swarnaprashan in reducing the frequency of illness in children by improving the immunity and increasing the body strength.CTRI/2021/05/033713ational Institute of Ayurveda Jaipur Rajasthan30
尚未招募
不适用
Investigate the safety and efficacy of small cell lung cancer,Kidney cancer and Primary liver cancer immunotherapyHistopathologically confirmed small cell lung cancer (SCLC)Histopathologically confirmed Kidney cancerHistopathologically confirmed Liver cancerACTRN12618001337268The First Teaching Hospital, Inner Mongolia Medical University50
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-ITOCTAPHARMA AG108
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-PLOCTAPHARMA AG108
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 18.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-HROCTAPHARMA AG108